Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, nAscent BioSciences, Beckman Coulter, Fluxion Biosciences, Cisbio, Cell Signaling Technology, TTP LabTech

Thermo Fisher Acquires Liquid Handling Consumables Firm
Thermo Fisher Scientific announced this week that it has acquired liquid handling consumables firm nAscent BioSciences for an undisclosed sum.
Thermo said that privately held nAscent’s product lines, including the PocketTip pipette tip, will be integrated into its existing liquid handling consumables business. The PocketTip combines nanoliter metering with microliter diluting in a pipette tip and can be used on most marketed automated liquid fandling platforms.
Thermo announced the acquisition at the LabAutomation conference in Palm Springs, Calif.

Beckman Coulter Moving Headquarters; Cutting Jobs at Palo Alto Facility
Beckman Coulter will move its existing headquarters from Fullerton, Calif., to the nearby city of Brea by the end of 2009. The firm also is cutting 158 jobs from its Palo Alto, Calif., operations, according to a notice posted last week on the website of the state’s Employment Development Department.
Mary Luthy, a Beckman Coulter spokesperson, told CBA News sister publication GenomeWeb Daily News this week that the firm is in the process of consolidating its Orange County, Calif., operations into its space in Brea, and that the firm would cease to have a presence in Fullerton once the relocation is completed.
The consolidation is part of a plan devised last year to identify areas where the firm could cut costs. Luthy said Beckman identified 100,000 square feet of wasted space in its facilities and expects it will identify even more excess space as it continues to evaluate its operations. The firm also plans to consolidate some of its West Coast warehouses into one center in Chino, Calif.
“At this time there are no planned layoffs,” associated with the relocation to Brea, said Luthy. “We have said that there may be some outsourcing or relocations.”
Luthy said that the reduction in staff in Palo Alto is part of Beckman’s plan to close its facilities there and move its centrifuge manufacturing operations to Indianapolis, which the firm announced a year ago.
She said that the job cuts would happen between now and September, as pieces of the manufacturing processes are relocated. The 158 staffers include those who decided against relocating and those who were not offered a position in Indianapolis, she said.

Fluxion Relocates HQ
Fluxion Biosciences announced this week that it has relocated its corporate headquarters to Oyster Point Business Park in South San Francisco, Calif. The company said that its new facility is significantly larger than its previous space, and will accommodate R&D, operations, sales and marketing, and customer service.
Fluxion said its new headquarters space has been designed to meet its requirements for the development of its high-throughput cell biology platforms, including state-of-the-art research labs, microfluidics clean rooms, and advanced technology development labs.

Cisbio Awards HTRF Certification to Beckman’s Paradigm Platform
Beckman Coulter announced this week that Cisbio has awarded its homogenous time-resolved fluorescence certification to Beckman’s Paradigm detection platform. 
Cisbio's certification verifies that the detection platform meets or exceeds performance criteria for HTRF assays. A new HTRF detection cartridge is now available for the modular Paradigm platform, bringing the total selection of detection cartridges to 10. The detection cartridges can be interchanged to meet different assay needs.
Paradigm, introduced earlier this year, is the first user-upgradeable and -configurable multimode reader, according to the manufacturer. 

CST and TTP LabTech Ink Deal to Develop HCS Assays For Cell P’Way Profiling
Cell Signaling Technology this week announced that it has entered into an assay development partnership agreement with TTP LabTech.
Under the agreement, CST will develop and validate antibodies on TTPLT's Acumen Explorer/eX3 microplate cytometric platform.
CST’s proprietary rabbit monoclonal technology and expertise in antibody-based assay technologies will be leveraged to develop and optimize a catalog of high- content assays for cellular pathway profiling on TTPLT's Acumen Explorer/eX3 platform.
CST will offer these Acumen high-content assays to the drug discovery market as CST products, as well as in profiling services.
Financial details of the agreement were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.